(S)-4-Chloro-3-hydroxybutyronitrile

We are (S)-4-Chloro-3-hydroxybutyronitrile CAS:127913-44-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(S)-4-Chloro-3-hydroxybutyronitrile
CAS.NO:127913-44-4
Synonyms:(S)-4-Chloro-3-hydroxybutyronitrile
(3S)-4-chloro-3-hydroxybutanenitrile
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 286.2±20.0 °C at 760 mmHg
Molecular Formula C4H6ClNO
Molecular Weight 119.549
Flash Point 126.9±21.8 °C
 
Specification:
Appearance:Colorless to light yellow transparent liquid
Assay:≥98.0%
Specific rotation:-15.0°~-19.0°
Moisture:≤0.15%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Rosuvastatin calcium(CAS:147098-20-2).

(S)-4-Chloro-3-hydroxybutyronitrile


Related News: In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.3-cloropropilmetildimetoxisilano CAS:18171-19-2 In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.4,4,5,5-tetramethyl-2-(3-(triphenylen-2-yl)phenyl)-1,3,2-dioxaborolane CAS:1115639-92-3 In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.84494-72-4 The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma’s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution.The bulk-buy program, which currently covers 25 types of medicines, allows no more than three successful bidders access to China’s public hospitals, where most Chinese people buy their drugs.

Related Products
Product Name
5-bromo-7,7-dimethylbenzo[c]fluorene View Details
Pregnenolone acetate View Details
DL-Butyrine View Details
Myristoyl Pentapeptide-8 manufacturer 5-Ethyl-2-pyridineethanol manufacturer (2’R)-2′-Deoxy-2′-fluoro-2′-methyl-uridine manufacturer 1,2-Difluoro-4-methyl-5-nitrobenzene manufacturer Angiotensin IV manufacturer